Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>On April 15, 2025, MetaVia Inc. (MTVA) announced positive results from the 4-week Phase 1 multiple ascending dose (MAD) trial of DA-1726 for the treatment of obesity.</li><li>The results showed a mean weight loss of 4.3% at Day 26 in the 32 mg dose with only mild gastrointestinal (GI) adverse events reported in 4/6 subjects, most of which resolved within 24 hours.</li><li>In addition, a mean reduction in waist circumference of 1.6 inches was demonstrated along with a mean lowering of -5.3 mg/dL in fasting blood glucose.</li></ul>

On April 15, 2025, MetaVia Inc. (MTVA) announced positive results from the 4-week Phase 1 multiple ascending dose (MAD) trial of DA-1726 for the treatment of obesity.The results showed a mean weight loss of 4.3% at Day 26 in the 32 mg dose with only mild gastrointestinal (GI) adverse events reported in 4/6 subjects, most of which resolved within 24 hours.In addition, a mean reduction in waist circumference of 1.6 inches was demonstrated along with a mean lowering of -5.3 mg/dL in fasting blood glucose.

MTVA：DA-1726の第1相MADデータは良好で、優れた忍容性プロファイルと26日目の平均体重減少は4.3%でした